InSimili

InSimili is a biotech startup that aims to revolutionize the drug development process. The company's unique technology recreates the human body's microenvironment in a lab setting, allowing for more accurate and efficient pre-clinical studies. This technology has the potential to reduce the need for in vivo testing, making the drug development process safer and more cost-effective.

InSimili's technology is particularly focused on regulating the concentration of oxygen and other agents at a microscale level. This is important because cells experience different levels of oxygen availability in the body, and being able to replicate this in a lab setting can lead to more accurate test results.

The company's business model is based on its patented solution, the INSIMILI ADvantage, which maintains a stable chemical microenvironment from cell culturing to imaging. This solution is standard compliant, cost-effective, and scalable, making it an attractive option for pharmaceutical companies and research institutes.

InSimili was founded in 2021 as a spin-off of the University of Bologna. The technology was invented by a group led by Professor Stefania Rapino and has already been used in prominent Italian research institutes. The company is led by Enrico Grassilli, a former lead microfluidics engineer at a Silicon Valley biotech startup, and Professor Rapino, professor of chemistry at the University of Bologna and inventor of the technology.

In summary, InSimili operates in the biotech and pharmaceutical market, serving clients such as pharmaceutical companies and research institutes. Its business model is based on providing a patented solution that improves the efficiency and safety of drug development.

Keywords: Biotech, Drug Development, Pre-Clinical Studies, In Vitro Testing, Oxygen Regulation, Microscale Technology, INSIMILI ADvantage, Cell Culturing, Imaging, University of Bologna Spin-Off.